Rat Monoclonal Anti-Heparan Sulfate Proteoglycan (Large) / Perlecan [Clone SPM255]
Referentie NB-36-00303X-P1BX
Formaat : 100ug
Merk : Neo Biotech
Free Shipping in the U.S. for orders over $1000. Shop Now>>
Heparan Sulfate Proteoglycan (Large) / Perlecan Antibody [SPM255]
This is an alt tag
Applications & Dilutions
Summary
This MAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan's strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
Product Properties & Targets
Functions
- Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.
- Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.
- The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.
Key References
- Ljubimov et. al., Lab Invest, 1995; 72:461-473.
- Couchman et. al., Matrix, 1989; 9:311-321.
- Folkvord et. al., J Histochem Cytochem, 1989; 37:105-113.
- Horiguchi et. al., J Histochem Cytochem, 1989; 37:961-970.
- Ljubimov et. al., Int J Cancer, 1992; 50:562-566.
- Guelstein et. al., Int J Cancer, 1993; 53:269-277.
PubMed Links
- https://pubmed.ncbi.nlm.nih.gov/1569102/
- https://pubmed.ncbi.nlm.nih.gov/1730768/
- https://pubmed.ncbi.nlm.nih.gov/16710414/
- https://pubmed.ncbi.nlm.nih.gov/8234307/
- https://pubmed.ncbi.nlm.nih.gov/11101850/
- https://pubmed.ncbi.nlm.nih.gov/1685141/
- https://pubmed.ncbi.nlm.nih.gov/1679749/
- https://pubmed.ncbi.nlm.nih.gov/2687294/
- https://pubmed.ncbi.nlm.nih.gov/15591058/
- https://pubmed.ncbi.nlm.nih.gov/12435733/
- https://pubmed.ncbi.nlm.nih.gov/11148217/
- https://pubmed.ncbi.nlm.nih.gov/11279527/
- https://pubmed.ncbi.nlm.nih.gov/11956183/
- https://pubmed.ncbi.nlm.nih.gov/12604605/
- https://pubmed.ncbi.nlm.nih.gov/12754519/
- https://pubmed.ncbi.nlm.nih.gov/16335952/
- https://pubmed.ncbi.nlm.nih.gov/17105986/
- https://pubmed.ncbi.nlm.nih.gov/18024432/
- https://pubmed.ncbi.nlm.nih.gov/19789387/
- https://pubmed.ncbi.nlm.nih.gov/19159218/
- https://pubmed.ncbi.nlm.nih.gov/22171320/
- https://pubmed.ncbi.nlm.nih.gov/24275569/
- https://pubmed.ncbi.nlm.nih.gov/21996443/
There are no reviews yet.